The drug industry has made billions by taking the stigma out of the once-taboo subject of erectile dysfunction. Now, it is targeting an equally delicate problem.
A number of pharmaceutical makers, including Johnson & Johnson, Pfizer and several biotech companies, are testing new drugs to treat the sexual complaint of premature ejaculation. The condition affects 15% to 30% of American men, according to many estimates. That makes it more common than erectile dysfunction, which affects about 10% of men. In the wake of the success of impotence drugs like Viagra, which are now a $2.5 billion-a-year industry world-wide, drug companies hope the emerging treatments could represent the next generation of blockbuster lifestyle drugs.
[WSJ]
No comments:
Post a Comment